Iodine (I-124) evuzamitide

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameIodine (I-124) evuzamitide
Drug Alias NameIodine-124I evuzamitideIodine (I-124) evuzamitideIodine (124I) evuzamitideAUR-01124I-APi1832 +[11] 
ClassificationDiagnostic agent (In vivo) > Radionuclide Imaging agentRadiation-emitting products > Nuclides > Iodine > 124ISmall molecules > Synthetic peptide > Peptide drug conjugate (PDC) +[4] 
Mechanisms of ActionSingle-photon emission-computed tomography enhancersPositron-emission tomography enhancersAmyloid binders
TargetsAmyloid
Therapy Area/IndicationsTransthyretin amyloidosisAmyloidosisCryopyrin-Associated Periodic Syndromes +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of TennesseeAttralus Inc
China Registration ClassN/A

Develop Information

Active CompaniesColumbia UniversityBayer AGThe University Of Tennessee Graduate School Of Medicine +[5] 
Inactive CompaniesN/A
Active IndicationsTransthyretin amyloidosisAmyloidosisCryopyrin-Associated Periodic Syndromes +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A